PapersFlow Research Brief
Psychedelics and Drug Studies
Research Guide
What is Psychedelics and Drug Studies?
Psychedelics and Drug Studies is a research field examining the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating depression, anxiety, and substance dependence, alongside their neurobiological mechanisms involving serotonin receptors and brain function.
This field encompasses 31,868 published works focused on psychedelic therapy's effects on psychological conditions. Studies demonstrate psilocybin's ability to reduce depression and anxiety in cancer patients, with sustained benefits observed in randomized trials. Research also investigates mystical experiences induced by psilocybin and their association with long-term psychological improvements.
Topic Hierarchy
Research Sub-Topics
Psilocybin Treatment-Resistant Depression
This sub-topic evaluates psilocybin-assisted psychotherapy for major depressive disorder unresponsive to conventional treatments. Researchers conduct RCTs measuring rapid and sustained symptom reduction via HAM-D scales.
MDMA-Assisted Therapy PTSD
This sub-topic investigates MDMA combined with psychotherapy for post-traumatic stress disorder, focusing on phase 3 trial outcomes. Researchers assess CAPS score improvements and long-term safety profiles.
Psychedelics Serotonin 2A Receptor Mechanisms
This sub-topic elucidates the role of 5-HT2A receptor agonism in psychedelic-induced alterations in perception and cognition. Researchers use pharmacological imaging and knockout models to dissect signaling pathways.
Mystical Experiences Psychedelic Therapy
This sub-topic correlates mystical-type experiences from MEQ scales with therapeutic outcomes in psychedelic trials. Researchers explore attribution to personality change and enduring well-being.
Psychedelics Substance Use Disorders
This sub-topic tests classic psychedelics like psilocybin and LSD for treating alcohol, tobacco, and opioid dependence. Researchers measure abstinence rates and craving reduction in controlled studies.
Why It Matters
Psychedelics and Drug Studies addresses unmet needs in mental health treatment through targeted applications. Griffiths et al. (2016) conducted a randomized double-blind trial with 51 cancer patients, where psilocybin produced substantial decreases in depression and anxiety that persisted for months. Ross et al. (2016) reported rapid symptom reduction in a similar trial, with 80% of participants showing significant improvements in anxiety and depression at 6-month follow-up. Carhart-Harris et al. (2016) demonstrated feasibility of psilocybin with psychological support, achieving response in all 12 patients with treatment-resistant depression after a single dose. These findings support psychedelics' role in oncology palliative care and refractory mood disorders, with Khantzian (1997) linking self-medication to substance use disorders treatable via such mechanisms.
Reading Guide
Where to Start
"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial" by Griffiths et al. (2016), as it provides a clear clinical trial example with quantifiable outcomes in a defined patient group.
Key Papers Explained
Griffiths et al. (2016) established psilocybin's efficacy in reducing cancer-related distress in a double-blind trial, building on their earlier work where Griffiths et al. (2006) characterized mystical experiences as key mechanisms. Ross et al. (2016) replicated these findings with rapid symptom reduction, confirming generalizability. Carhart-Harris et al. (2016) extended to treatment-resistant depression, showing feasibility in non-cancer populations. Nichols (2016) provides pharmacological context, while Khantzian (1997) links to addiction self-medication.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent works emphasize open-label feasibility and randomized trials in depression and cancer anxiety, with no new preprints available. Frontiers include scaling psychological support protocols and identifying biomarkers for responders.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The Self-Medication Hypothesis of Substance Use Disorders: A R... | 1997 | Harvard Review of Psyc... | 3.0K | ✕ |
| 2 | International Union of Pharmacology classification of receptor... | 1994 | Pharmacological Reviews | 3.0K | ✕ |
| 3 | Cognitive Therapy and the Emotional Disorders | 1977 | American Journal of Ps... | 2.9K | ✕ |
| 4 | The Hero with a Thousand Faces | 1949 | — | 2.8K | ✕ |
| 5 | Psilocybin produces substantial and sustained decreases in dep... | 2016 | Journal of Psychopharm... | 2.0K | ✓ |
| 6 | Psychedelics | 2016 | Pharmacological Reviews | 1.6K | ✓ |
| 7 | Psilocybin can occasion mystical-type experiences having subst... | 2006 | Psychopharmacology | 1.6K | ✕ |
| 8 | Rapid and sustained symptom reduction following psilocybin tre... | 2016 | Journal of Psychopharm... | 1.6K | ✓ |
| 9 | Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform | 2003 | Science | 1.5K | ✕ |
| 10 | Psilocybin with psychological support for treatment-resistant ... | 2016 | The Lancet Psychiatry | 1.5K | ✓ |
Frequently Asked Questions
What effects does psilocybin have on cancer patients with depression and anxiety?
In a randomized double-blind trial, psilocybin produced substantial and sustained decreases in depression and anxiety among 51 patients with life-threatening cancer. Griffiths et al. (2016) found these effects persisted beyond 6 months in many participants. The treatment involved a single high dose compared to a placebo.
How does psilocybin treatment work for treatment-resistant depression?
Psilocybin with psychological support showed feasibility in an open-label study of 12 patients with treatment-resistant depression. Carhart-Harris et al. (2016) observed rapid antidepressant effects, with all patients responding after one or two doses. Benefits lasted up to 3 months post-treatment.
What are mystical-type experiences induced by psilocybin?
Psilocybin occasions mystical-type experiences with substantial personal meaning and spiritual significance. Griffiths et al. (2006) reported these experiences in healthy volunteers under controlled conditions. Such experiences correlated with sustained positive changes in attitudes and behavior.
What is the self-medication hypothesis in substance use disorders?
The self-medication hypothesis posits that individuals use substances to relieve specific painful affect states. Khantzian (1997) derived this from clinical observations of patients with addictive disorders. Specific drug effects match targeted symptom relief.
How do serotonin receptors relate to psychedelics?
Psychedelics interact with 5-hydroxytryptamine (serotonin) receptors classified by the International Union of Pharmacology. Hoyer et al. (1994) detailed receptor subtypes involved in neurotransmitter effects. Nichols (2016) reviewed psychedelics' actions on these receptors in therapeutic contexts.
Open Research Questions
- ? What are the long-term neurobiological changes induced by repeated psilocybin administration in treatment-resistant depression?
- ? How do mystical experiences from psychedelics mediate sustained therapeutic outcomes in anxiety disorders?
- ? Which serotonin receptor subtypes most critically underlie psilocybin's antidepressant effects in cancer patients?
- ? Can the self-medication hypothesis predict differential responses to psychedelic-assisted therapy across substance use disorders?
- ? What psychological support protocols optimize outcomes in MDMA or psilocybin trials for PTSD?
Recent Trends
The field maintains 31,868 works with established high-citation papers from 1997-2016, including Griffiths et al. at 2025 citations and Carhart-Harris et al. (2016) at 1465 citations.
2016No growth rate data or recent preprints/news indicate steady incorporation of 2016 trial results into clinical practice.
Core focus remains psilocybin trials for depression and anxiety.
Research Psychedelics and Drug Studies with AI
PapersFlow provides specialized AI tools for Psychology researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Social Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Psychedelics and Drug Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Psychology researchers